Log in
(Ad)
Its partners include AT&T, Verizon, Sprint and T-Mobile. It owns more than 200 patents. And analysts say it has "home-run potential." Yet this 5G superstock trades for only $5 a share.

NASDAQ:TLRY - Tilray Stock Price, Forecast & News

$20.85
-0.24 (-1.14 %)
(As of 01/23/2020 06:00 AM ET)
Today's Range
$20.72
Now: $20.85
$22.23
50-Day Range
$15.33
MA: $17.83
$21.36
52-Week Range
$15.01
Now: $20.85
$89.88
Volume5.47 million shs
Average Volume5.77 million shs
Market Capitalization$2.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.87
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLRY
CUSIPN/A
CIKN/A
Phone844-845-7291

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.13 million
Book Value$2.12 per share

Profitability

Net Income$-67,720,000.00

Miscellaneous

EmployeesN/A
Market Cap$2.10 billion
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive TLRY News and Ratings via Email

Sign-up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

And Reuters magazine calls this type of trading "the new baby boomer hobby." An anonymous trader -- living at the base of the Smoky Mountains -- just released a free report revealing a step-by-step system to generating an extra $5,000 per month in income thanks to this trading strategy. The report is free until Sunday.

Tilray (NASDAQ:TLRY) Frequently Asked Questions

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.05. The business earned $51.10 million during the quarter, compared to the consensus estimate of $49.57 million. Tilray had a negative return on equity of 40.30% and a negative net margin of 97.39%. The company's revenue for the quarter was up 411.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.08) EPS. View Tilray's Earnings History.

When is Tilray's next earnings date?

Tilray is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Tilray.

What price target have analysts set for TLRY?

19 brokerages have issued 1-year target prices for Tilray's stock. Their forecasts range from $18.00 to $81.10. On average, they expect Tilray's share price to reach $40.82 in the next year. This suggests a possible upside of 95.8% from the stock's current price. View Analyst Price Targets for Tilray.

What is the consensus analysts' recommendation for Tilray?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 3 sell ratings, 12 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tilray.

What are Wall Street analysts saying about Tilray stock?

Here are some recent quotes from research analysts about Tilray stock:
  • 1. According to Zacks Investment Research, "Tilray, Inc. is a pharmaceutical company. It develops cannabis based medicines, drugs, drops and oil products. Tilray, Inc. is based in NANAIMO, Canada. " (10/25/2019)
  • 2. Jefferies Financial Group Inc analysts commented, "We initiate at Underperform, PT $61. With arguably inferior positioning in parts of its business vs. certain peers (questionable Canada rec approach, less impressive US optionality, too much value credited to ABI/ABG), we struggle to justify the current valuation. We appreciate it is well placed in medical but future value here will be driven by IP for which little visibility near term. Its share structure also raises risk of increased volatility." (3/8/2019)

Has Tilray been receiving favorable news coverage?

Media headlines about TLRY stock have trended somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tilray earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Tilray.

Who are some of Tilray's key competitors?

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Advanced Micro Devices (AMD), Aphria (APHA) and GW Pharmaceuticals PLC- (GWPH).

Who are Tilray's key executives?

Tilray's management team includes the folowing people:
  • Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
  • Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
  • Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
  • Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company acted as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Who are Tilray's major shareholders?

Tilray's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Commerzbank Aktiengesellschaft FI (0.07%), AdvisorShares Investments LLC (0.03%), Alpine Global Management LLC (0.02%) and Gainplan LLC (0.01%). Company insiders that own Tilray stock include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr, Mark Castaneda and Michael Auerbach. View Institutional Ownership Trends for Tilray.

Which institutional investors are buying Tilray stock?

TLRY stock was purchased by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, Alpine Global Management LLC, Commerzbank Aktiengesellschaft FI and Gainplan LLC. Company insiders that have bought Tilray stock in the last two years include Brendan Kennedy and Edward Wood Pastorius Jr. View Insider Buying and Selling for Tilray.

How do I buy shares of Tilray?

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $20.85.

How big of a company is Tilray?

Tilray has a market capitalization of $2.10 billion and generates $43.13 million in revenue each year. The company earns $-67,720,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. View Additional Information About Tilray.

What is Tilray's official website?

The official website for Tilray is http://www.tilray.com/.

How can I contact Tilray?

Tilray's mailing address is 1100 Maughan Road, Nanaimo A1, V9X IJ2. The company can be reached via phone at 844-845-7291.


MarketBeat Community Rating for Tilray (NASDAQ TLRY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  397 (Vote Outperform)
Underperform Votes:  434 (Vote Underperform)
Total Votes:  831
MarketBeat's community ratings are surveys of what our community members think about Tilray and other stocks. Vote "Outperform" if you believe TLRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel